The invention relates to tetrahydroquinolinone derivatives as well as
their pharmaceutially acceptable salts. The invention further relates to
a process for the preparation of such compounds. The compounds of the
invention are group I mGluR antagonists and are therefore useful for the
control and prevention of acute and/or chronic neurological disorders.